Neurotechnology Market Report 2025

The neurotechnology market size has grown rapidly in recent years. It will grow from $15.38 billion in 2024 to $17.39 billion in 2025 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to increased research funding, aging population, neurological disorders prevalence, regulatory support, government initiatives.

The neurotechnology market size is expected to see rapid growth in the next few years. It will grow to $29.8 billion in 2029 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to regulatory advancements, genomics and neurological disorders, telemedicine in neurology, precision medicine adoption, development of closed-loop systems. Major trends in the forecast period include neuroinformatics advancements, neuroplasticity interventions, brain mapping initiatives, remote monitoring solutions, non-invasive brain stimulation.

The anticipated increase in the prevalence of neurological conditions is set to drive the growth of the neurotechnology market in the coming years. Neurological conditions encompass various disorders or diseases affecting the brain, including Alzheimer's disease, Parkinson's disease, epilepsy, and migraine. Neurotechnology is playing a crucial role in diagnosing and treating these conditions through methods such as brain imaging, neurostimulation, neurofeedback, and brain-computer interfaces. For example, as of January 2022, the American Heart Association Inc. projected that Alzheimer's disease and related dementias would impact approximately 9.3 million people in the United States by 2060. Additionally, according to the World Health Organization (WHO) in February 2023, an estimated 5 million people worldwide are expected to be diagnosed with epilepsy annually. Therefore, the increasing prevalence of neurological conditions is a driving force behind the growth of the neurotechnology market.

The increasing healthcare expenditure is expected to propel the growth of the neurotechnology market in the coming years. Healthcare expenditure refers to the total spending on healthcare-related goods and services within a particular healthcare system or economy. This spending supports the development and implementation of neurotechnology by promoting research, improving access to advanced equipment, enhancing education and training, facilitating clinical trials, ensuring regulatory oversight, and making innovative treatments more accessible for patients requiring neurological care. For instance, in 2022, the Office for National Statistics, a UK-based national statistics organization, reported that UK healthcare expenditure reached approximately $354.88 billion (£283 billion), representing a nominal increase of 0.7% compared to the previous year. Thus, the rise in healthcare expenditure is driving the growth of the neurotechnology market.

Technological advancements represent a significant trend gaining momentum in the neurotechnology market, with companies adopting innovative technologies to maintain their market positions. For instance, in November 2022, Blackrock Neurotech, a biotechnology company based in the United States, introduced Neuralace, a next-generation technology in neurotechnology. Neuralace, resembling a lace thinner than an eyelash, can cover large areas of the brain's surface. Designed as an ultra-high channel count, flexible electrode, Neuralace provides insights into the technology powering future brain-computer interfaces (BCIs). The system assists patients in regaining tactile function, limb and prosthetic movement, and the ability to control digital devices.

Major players in the neurotechnology market are concentrating on developing advanced therapeutic solutions, including the endovascular brain-computer interface (BCI), to enhance cognitive function and restore mobility for patients with neurological impairments. The endovascular BCI allows for direct neural access through blood vessels, enabling better interaction and treatment options for individuals with neurological disorders. For instance, in April 2024, Synchron, a Sweden-based software company specializing in advanced synchronization technologies for seamless data integration and management, launched the Patient Registry for its Stentrode Brain-Computer Interface. This technology is designed to interpret brain signals and restore motor intent, allowing individuals with limited mobility to control digital devices hands-free. Implanted via a non-invasive endovascular procedure, it wirelessly transmits motor intent from the brain, helping severely paralyzed patients regain independence. This groundbreaking technology marks a significant advancement in assistive solutions, facilitating daily activities such as communication and access to essential services.

In April 2022, Blackrock Neurotech, a U.S.-based biotechnology company, acquired Mindx Corporation for an undisclosed amount. This acquisition expands Blackrock's software portfolio and positions the company to offer integrated BCI products with cutting-edge features, enhancing its ability to provide a full-stack solution to customers. Mindx Corporation, based in the United States, is known for developing a neuron technology framework for use in spatial computing applications.

Major companies operating in the neurotechnology market include General Electric, Medtronic PLC, Koninklijke Philips N.V., Shimadzu Corporation, EndoStim Inc., Elekta AB, Natus Medical Incorporated, Abbott, Boston Scientific Corporation, Cleveland Medical Devices Inc., Nihon Kohden Corporation, LivaNova PLC, Siemens Healthcare Private Limited, Hitachi Medical Corporation, Cochlear Limited, Advanced Bionics AG (Sonova), NeuroPace Inc., NeuroSigma Inc., NeuroMetrix Inc., NeuroSky Inc., NeuroVigil Inc., Neurotech Pharmaceuticals Inc., Neurotech International Limited, NeurotechEU, Neurotech Solutions, Neurotech Reports, Neurotech Research Development.

North America was the largest region in the neurotechnology market in 2024. Europe is expected to be the fastest-growing region in the neurotechnology market report during the forecast period. The regions covered in the neurotechnology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neurotechnology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Neurotechnology involves the study and interaction with the nervous system, encompassing the brain and other components of the nervous system. In clinical settings, neurotechnology is utilized to influence the brain or nervous system, often in therapeutic or rehabilitative contexts.

The primary neurotechnology applications include addressing conditions such as cognitive disorders, pain treatment, urinary and fecal incontinence, epilepsy, Parkinson's disease, hearing conditions, sleep disorders, depression, and various others. Cognitive disorders signify a significant decline in an individual's cognitive function to an extent that, without treatment, regular social activities become challenging. The diverse types of neurotechnology include imaging modalities, neurostimulation, cranial surface measurement, neurological implants, and others. These technologies find application in ambulatory surgical centers, hospitals, homecare facilities, and other medical settings.

The neurotechnology market research report is one of a series of new reports that provides neurotechnology market statistics, including neurotechnology industry global market size, regional shares, competitors with a neurotechnology market share, detailed neurotechnology market segments, market trends and opportunities, and any further data you may need to thrive in the neurotechnology industry. This neurotechnology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neurotechnology market includes revenues earned by entities from neuro-rehabilitative treatment, heart rate variability, electroencephalography, and neurostimulation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The neurotechnology market consists of sales of brain-computer interfaces (BCIs), neurostimulation devices, virtual reality (VR), and prosthetic limb devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.